Congress intelligence platform

Walk into every congress ready.

Intelliscope scores every abstract against your portfolio and competitors, turns priorities into a coordinated coverage plan, and keeps every decision, note, and interaction linked and searchable, congress after congress.

Your congresses, competitors, KOLs, and portfolio in one place.

Aster Bio

Needs attention

25

Global Oncology Forum 20278
Translational Oncology Summit 20275

Conferences

3Tracked
2,840Docs summarized

Competitor

3Monitored
84Linked abstracts

Portfolio

3Products added
67Linked abstracts

Ongoing

Incoming

Translational Oncology Summit 2027

San Diego, California, USA

Abstract release August 1, 2027

Global Oncology Forum 2027

San Antonio, TX, US

Abstract release July 15, 2027

A short window, thousands of data points, no shared system.

The moment abstracts are released, your team has days to decide what matters across thousands of new data points. Today that work lives in spreadsheets, slide decks, email threads, and individual memory. It is slow, it is inconsistent, and most of it is gone by the next congress.

Sources

Abstracts

1,362 ingested

Competitors

9 tracked

Portfolio

assets + MoA

Priorities

exec + TA focus

Intelliscope
ingest / score / route

Outputs

Ranked abstracts

with rationale

Coverage plan

owned by session

Briefings

field-ready

Institutional memory

across cycles

01Pre-congress

Know what matters before you arrive.

Turn thousands of abstracts into a focused plan. Find the science that matters to your company, the people behind it, and the sessions your team needs to cover.

ONCOLOGY FRONTIERS 2027

Find your signal.

OncologyPortfolio + competitors
LB-214High

KRAS G12C: response durability

Phase II · Oral presentation

P-082High

Resistance after targeted therapy

Oncology · Research abstract

O-136Medium

ctDNA-guided treatment selection

Oncology · Research abstract

Why it matters to Aster Bio

Connected to your portfolio.

Relevant to NS-17 and your focus on KRAS G12C resistance.

NS-17 · KRAS G12C
Intelliscope / Pre-congress
Abstracts to consider
6,000
First pass per abstract
3 min
Manual screening time
300 h

Illustrative workload: 6,000 abstracts × 3 minutes = 300 hours. This models manual screening effort, not measured time savings.

02During congress
Your congress, in your pocket.

Your team, connected. Your congress, in your pocket.

Feature 01 / 04

Your day, on your phone

9:415G ▰
Oncology Frontiers 2027

Calendar

Saturday, 12 June3 assignments · Your local time
08:00

Scientific team huddle

Meeting room 2

08:30

KRAS G12C readout

Hall A · LB-214

Assigned to you
10:00

Resistance mechanisms

Poster hall · P-082

Conferences
Notes
Calendar
Profile

See assigned sessions and meetings, times, locations, and conflicts in your personal mobile calendar.

UP NEXT / 08:30KRAS G12C readout

Hall A · Abstract LB-214

Assigned to you
03Post-congress

Turn every congress into a stronger starting point.

ASTER BIO / MEDICAL AFFAIRSCONGRESS READOUT

Oncology
Frontiers 2027

Scientific findings, competitive context, and field insights.

01 / Key finding

Response durability is a priority for follow-up.

The KRAS G12C readout raises questions about prior-treatment subgroups relevant to NS-17.

1 · Abstract LB-2142 · Maya’s field note
Competitive context

A competing approach in the same patient population.

Next discussion

Revisit the subgroup data with Dr. Ana Silva.

Congress readoutScience + team observations

Generate congress reports

Bring scientific findings, competitive developments, and team observations together in an evidence-linked congress readout.

From the congress report

Response durability is a priority for follow-up.

NS-17KRAS G12C
Original science

Abstract LB-214

KRAS G12C: response durability

Dr. Ana Silva
Captured in the field

Maya’s observation

Review the prior-treatment subgroup.

12 June · 09:12

Keep the evidence close

Trace a conclusion back to its abstract, session, researcher, and field notes. Revisit the discussion behind the finding.

INSTITUTIONAL MEMORY

Every congress
adds to the picture.

2026

The first questions

Portfolio priorities and KOL context.

2027

New evidence, more context

This congress’s findings, report, and field notes.

Next

A stronger starting point

Earlier findings inform what to look for and who to meet.

KRAS G12C / Continuing contextNS-17 · Competitors · Dr. Ana Silva

Build compounding memory

Carry portfolio insights, competitor context, and KOL relationships from one congress into preparation for the next.

FAQ

Before your next congress.

A few answers about the science, the workflow, and getting your team started.

IntelliScope is a congress intelligence and execution platform built for Medical Affairs, Competitive Intelligence, and scientific congress teams. It connects abstract prioritization, team coverage planning, field capture, KOL context, competitor intelligence, and post-congress retrieval in one searchable system.

The countdown's already running.

Your next congress is closer than the prep work suggests. See Intelliscope on a live workflow, configured to your portfolio and competitor watchlist.

Next major congress

ESMO 2026

Madrid

Countdown

Abstracts release0d

Congress opens19d

Request a demo